As a late clinical-stage biopharmaceutical company focused on oncology, our business model is to in-license novel compounds, develop them through clinical stages, and then seek to commercialize them through out-licensing arrangements with biotechnology and pharmaceutical companies or evaluating, on a case-by-case basis, the commercialization of our therapeutic candidates independently.
Our lead program, motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem-cell mobilization for autologous bone-marrow transplantation and has reported positive results from pharmacoeconomic studies. These outstanding results support the goal of motixafortide becoming the standard of care mobilization agent in autologous bone-marrow transplantation, and in this regard, after a successful pre-NDA meeting with the FDA, we are currently preparing an NDA submission in mid-2022.read more